RBC Capital initiated coverage of Damora Therapeutics (DMRA) with an Outperform rating and $40 price target The firm believes the company is “capitalizing on an increasingly validated approach” of using mCALR antibodies in myeloproliferative neoplasms. This helps de-risk Damora’s early stage pipeline, the analyst tells investors in a research note. RBC expects Damora shares to appreciate as its portfolio advances.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMRA:
- Damora Therapeutics initiated with an Outperform at Evercore ISI
- Damora Therapeutics Announces Major Leadership and Board Overhaul
- Damora names Peter Harwin chairman, appoints Spyre Therapeutics CEO to board
- Damora Therapeutics appoints Jennifer Jarrett as CEO
- Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway